New research suggests GLP-1 weight-loss medications are reducing spending on snacks, fast food and groceries, forcing food companies and retailers to rethink consumer demand.
LONDON/NEW YORK, June 2026 — U.S. households using GLP-1 weight-loss medications reduced grocery spending by an average of 5.3% within six months of adoption, according to research by Cornell University, providing some of the clearest evidence yet that obesity drugs are beginning to reshape consumer behavior beyond healthcare.
Among higher-income households, grocery spending fell by 8.2%, while spending at fast-food restaurants, coffee shops and other limited-service eateries declined by approximately 8%. Purchases of savory snacks fell by more than 10%, according to the study.
The findings are drawing growing attention from food manufacturers, retailers, restaurant operators and investors assessing how rapidly expanding obesity-drug adoption could alter demand across the food industry.
GLP-1 medications including Wegovy, Ozempic, Zepbound and Mounjaro suppress appetite and increase feelings of fullness. Originally developed to treat diabetes and obesity, the drugs have become one of the fastest-growing segments of the global pharmaceutical market.
“We’re seeing evidence that these medications are changing household food demand in measurable ways,” said Sylvia Hristakeva, assistant professor at Cornell University and co-author of the study.
Researchers identified declines across categories including snacks, sweets, baked goods and highly processed foods. Spending at fast-food restaurants and other limited-service establishments also fell after households adopted GLP-1 therapies.
A 5.3% reduction in grocery spending may appear modest at the household level. Across millions of users, however, the shift could represent billions of dollars in changing food expenditures annually.
Food companies are already adjusting.
Nestlé launched its Vital Pursuit product line emphasizing protein, fiber and portion control. Conagra Brands introduced GLP-1-friendly labeling for selected Healthy Choice products, while Danone expanded protein-focused offerings aimed at consumers seeking nutritional support during weight loss.
Nestlé executives have argued that obesity medications are likely to change food preferences rather than eliminate food demand altogether. Whether higher-value nutrition-focused products can offset lower consumption volumes remains one of the industry’s biggest questions.
Retailers are also beginning to detect changes in purchasing patterns. Walmart executives have publicly acknowledged observing reduced purchases in certain food categories among customers using GLP-1 medications, comments that attracted significant attention across consumer and retail sectors.
Adoption continues to accelerate.
Novo Nordisk reported that global branded GLP-1 obesity-treatment volumes grew 104% during 2025 while maintaining approximately 59.6% of the branded obesity-treatment market. JPMorgan estimates that roughly 25 million Americans could be using GLP-1 medications by 2030, compared with approximately 10 million users in 2025.
Novo Nordisk has also projected that oral obesity medications could account for more than one-third of the global GLP-1 market by 2030, potentially expanding access to treatment beyond injectable products.
Forecasts for the sector remain substantial. Goldman Sachs previously reduced its estimate for the global obesity-drug market to approximately $95 billion by 2030 from an earlier forecast of $130 billion, citing competition and pricing pressure. IQVIA estimates annual sales could eventually range between roughly $105 billion and $200 billion, depending on adoption rates, reimbursement policies and future product development.
Although much of the discussion has focused on the United States, the trend is increasingly global.
In the United Kingdom, surveys suggest households using GLP-1 medications are reducing grocery purchases while increasing interest in nutrition-focused products. Retailers including Marks & Spencer and Ocado have introduced products aimed at consumers seeking higher protein intake and greater satiety.
China is emerging as another major growth market. Reuters reported that sales of GLP-1 products through major Chinese online platforms reached approximately 1.4 billion yuan during the first quarter of 2026, suggesting that consumption shifts observed in the United States could eventually extend to the world’s second-largest consumer market.
Uncertainty remains over the long-term impact of obesity medications on food consumption.
A study published in JAMA Network Open found that 36.5% of patients discontinued GLP-1 treatment within one year, with discontinuation rates exceeding 50% among some obesity-only patient groups.
Cost, side effects, insurance limitations and personal preference remain significant barriers to continued use. Research also suggests some food-spending patterns may rebound after treatment ends.
The industry’s central question is no longer whether GLP-1 medications influence food spending. It is whether those changes persist long enough to reshape long-term consumer behavior across the global food economy.
